The introduction of measurements of hormone receptors in breast cancer tumor specimens provides a major advance in selection of patients likely to have hormone-dependent cancers. Endocrine adjuvant treatment for estrogen-positive breast cancers in both pre- and postmenopausal women has been shown to be effective in delaying recurrence. Whenever possible, estrogen and progesterone receptors should be measured in tumor tissue from all patients with breast cancer.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1016/s0039-6109(16)43487-0 | DOI Listing |
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!